<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01467713</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-375SL_203</org_study_id>
    <secondary_id>U1111-1124-4675</secondary_id>
    <nct_id>NCT01467713</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenance Treatment of Bipolar I Disorder</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375SL as an Adjunctive Therapy to Treatment-as-Usual in the Maintenance Treatment of Bipolar I Disorder in Adult Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of ramelteon, once nightly
      before bedtime (QHS), sublingual (SL), in the maintenance treatment of Bipolar I Disorder in
      adult patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TAK-375SL (ramelteon sublingual formulation) is being developed by Takeda Pharmaceutical
      Company Limited as an adjunctive treatment in the maintenance therapy of bipolar I disorder.

      Participants will be seen twice a month for the first two months and then once every month up
      to the end of the 9-month treatment period. Participants who complete the 9-month treatment
      period will have a follow-up visit approximately seven days after the last visit. A safety
      followup phone call will be made 30 days after completion of the 9-month treatment period.

      Based on the recommendation of the Independent Data Monitoring Committee which determined
      that the study data had met pre-determined criteria for futility, Takeda has made a decision
      to terminate the study. No safety concerns were identified by the Independent Data Monitoring
      Committee
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business Decision; No Safety Concerns.
  </why_stopped>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time From Randomization to Any Relapse</measure>
    <time_frame>Randomization to Month 12 double-blind treatment period</time_frame>
    <description>The time from randomization to relapse over 12 months double-blind treatment period as determined by the Principal Investigator (PI) or defined by any of the following criteria: depression [Montgomery-Åsberg Depression Rating Scale (MADRS) score ≥16]; mania/hypomania [Young Mania Rating Scale (YMRS) total score ≥14]; mixed episode [MADRS score ≥16 and YMRS total score ≥16]; or, whether participant receives psychiatric hospitalization for bipolar disorder, electroconvulsive therapy (ECT) or any psychotropic medication change prescribed for the treatment of depression, mania/hypomania or mixed episodes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time From Randomization to Relapse Due to Depression</measure>
    <time_frame>Randomization to Month 12 double-blind treatment period</time_frame>
    <description>Relapse due to depression determined by any of the following criteria during the 12-month double-blind treatment period: PI judgment, MADRS ≥16, psychiatry hospitalization, ECT or any psychotropic medication change prescribed for the treatment of depressive episodes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Randomization to Relapse Due to Mania/Hypomania or Mixed Episode</measure>
    <time_frame>Randomization to Month 12 double-blind treatment period</time_frame>
    <description>Relapse due to mania/hypomania or mixed episode is determined by any of the following criteria: PI judgment, mania/hypomania [YMRS ≥16], mixed episode [MADRS ≥16 and YMRS ≥16], psychiatry hospitalization, ECT or any psychotropic medication change prescribed for the treatment of mania/hypomania or mixed episodes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Randomization to Relapse Due to Depression From PI Judgement and/or MADRS ≥16</measure>
    <time_frame>Randomization to Month 12 double-blind treatment period</time_frame>
    <description>The time from randomization to relapse event during the 12 month double-blind treatment period due to depression, determined by the PI judgement and/or a MADRS score ≥16. MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (i.e., apparent sadness, reported sadness, inner tension, etc.) rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score range from 0 to 60. Higher scores indicate greater severity of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Randomization to Relapse Due to Mania/Hypomania</measure>
    <time_frame>Randomization to 12 Month double-blind treatment period</time_frame>
    <description>Relapse due to mania/hypomania is determined by the primary investigator (PI) judgement and/or a YMRS total score ≥16. YMRS is a 11 item scale with four items scale to assess manic symptoms, rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe), with 7 items rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe) with higher scores reflecting greater levels of mania. The YMRS total score is calculated as the sum of the 11 individual item scores and ranges from 0-60.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Randomization to Relapse Due to Mixed Episode</measure>
    <time_frame>Randomization to Month 12 double-blind treatment period</time_frame>
    <description>Relapse due to Mixed episode is determined by PI judgement and/or MADRS score ≥16 and YMRS total score ≥16. MADRS is a 10-item scale that measures overall severity of depressive symptoms rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score range from 0 to 60. YMRS is a four item scale to assess manic symptoms, rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe), with 7 items rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score is calculated as the sum of the 11 individual item scores and ranges from 0-60.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Randomization to Relapse Due to Psychiatric Hospitalization for Bipolar Disorder</measure>
    <time_frame>Randomization to Month 12 double-blind treatment period</time_frame>
    <description>The time from randomization to relapse event during the 12 months double-blind treatment period due to psychiatric hospitalization for bipolar disorder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Randomization to Relapse Due to Electroconvulsive Therapy (ECT) Administration</measure>
    <time_frame>Randomization to Month 12 double-blind treatment period</time_frame>
    <description>The time from randomization to relapse event during the 12 month double-blind treatment period due to ECT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Randomization to Relapse Due to Psychotropic Medication Change Prescribed for the Treatment of Depression, Mania/Hypomania or Mixed Episodes</measure>
    <time_frame>Randomization to Month 12 double-blind treatment period</time_frame>
    <description>The time from randomization to relapse event during the 12 month double-blind treatment period due to any psychotropic medication change prescribed for the treatment of depression, mania/hypomania or mixed episode(s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Randomization to Study Withdrawal for Any Reason</measure>
    <time_frame>Randomization to Month 12 double-blind treatment period</time_frame>
    <description>The time from randomization to study withdrawal during the 12 month double-blind treatment period. Withdrawal includes pretreatment event/adverse event; liver function test abnormalities; major protocol deviation; lost to follow-up; voluntary withdrawal; study termination; pregnancy; lack of efficacy; participant has a depressive, mania/hypomania or mixed episode; is hospitalized for psychiatric reasons; receives electroconvulsive therapy for bipolar disorder; receives any psychotropic medication change prescribed for the treatment of depression, mania/hypomania or mixed episodes; or any other reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life, Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF) Total Score</measure>
    <time_frame>Baseline and Months 1, 2, 3, 4, 5, 6, 7, 8, 10 and 12</time_frame>
    <description>Q-LES-Q-SF is a self-administered 16-item questionnaire to assess the degree of enjoyment and satisfaction experienced by patients in various areas of daily functioning. It includes 30 items across five subscales (daily activities, clothing, diet/food habits, relationship, psychological well-being and distress), scored on a 6-point Likert scale with subscale and total score ranging from 0 (none) to 5 (all the time). For reporting purposes, the scores are reversed and higher scores reflect improved quality of life and positive changes relative to baseline indicate improved quality of life.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">642</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ramelteon SL placebo-matching, tablets, sublingual (SL) [dissolved under the tongue], once daily, every night at bedtime for up to 9 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ramelteon SL 0.1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ramelteon SL 0.1 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ramelteon SL 0.4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ramelteon SL 0.4 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ramelteon SL 0.8 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ramelteon SL 0.8 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramelteon SL</intervention_name>
    <description>Ramelteon sublingual (SL) tablets</description>
    <arm_group_label>Ramelteon SL 0.1 mg</arm_group_label>
    <arm_group_label>Ramelteon SL 0.4 mg</arm_group_label>
    <arm_group_label>Ramelteon SL 0.8 mg</arm_group_label>
    <other_name>TAK-375SL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Ramelteon sublingual (SL) placebo-matching tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. In the opinion of the investigator, the participant is capable of understanding and
             complying with protocol requirements.

          2. The participant or, when applicable, the participant's legally acceptable
             representative signs and dates a written, informed consent form and any required
             privacy authorization prior to the initiation of any study procedures.

          3. The participant suffers from bipolar I disorder, according to Diagnostic and
             Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
             criteria and is confirmed by the Structured Clinical Interview for DSM Disorders
             (SCID).

          4. The participant is a man or woman aged between 18 and 75 years, inclusive.

          5. The participant has an identified caregiver or person responsible (e.g. family member,
             spouse, case worker or nurse at a residential living (facility) that is considered
             reliable by the investigator.

          6. The most recent mood episode (depression, mania, mixed episode) is within the past 9
             months from screening.

          7. The participant has been in remission in the opinion of the principal investigator
             (PI) for at least 8 weeks prior to baseline from their most recent mood episode.

          8. The participant has a Montgomery-Åsberg Depression Rating Scale (MADRS) total score
             ≤12 at the Screening and Baseline visits.

          9. The participant has a Young Mania Rating Scale (YMRS) score of ≤10 both at the
             Screening and Baseline visits.

         10. The participant has a Clinical Global Impression Scale - Severity (CGI-S) score of ≤2
             at the Screening and Baseline visits.

         11. Hamilton Rating Scale for Anxiety (HAM-A) score is ≤21 at Screening and Baseline
             visits.

         12. The participant's medications for bipolar I disorder are stable i.e., no dose
             adjustment has been made for at least 8 weeks prior to the randomization

         13. A male participant who is nonsterilized and sexually active with a female partner of
             childbearing potential agrees to use adequate contraception from signing of informed
             consent through the duration of the study and for 30 days after the last dose.

         14. A female participant of childbearing potential who is sexually active with a non
             sterilized male partner agrees to use routinely adequate contraception from signing of
             informed consent throughout the duration of the study and for 30 days after the last
             dose.

        Exclusion Criteria:

          1. The participant has received any investigational compound &lt;30 days before Screening or
             5 half-lives prior to Screening.

          2. The participant has ever received ramelteon in a previous clinical study or has ever
             used ramelteon.

          3. The participant is an immediate family member, study site employee, or is in a
             dependent relationship with a study site employee who is involved in conduct of this
             study (eg, spouse, parent, child, sibling) or may consent under duress.

          4. The participant has one or more of the following:

               -  Any current psychiatric disorder which is the primary focus of treatment other
                  than bipolar I disorder as defined in the DSM-IV-TR, as assessed by the SCID.

               -  Current or history of: schizophrenia or any other psychotic disorder, including
                  major depression with psychotic features, bipolar depression with psychotic
                  features (with the exception of psychosis associated with a manic or mixed
                  episode), obsessive-compulsive disorder (OCD), mental retardation, organic mental
                  disorders, or mental disorders due to a general medical condition as defined in
                  the DSM-IV-TR.

               -  Current diagnosis or history of alcohol or other substance abuse (excluding
                  nicotine or caffeine) as defined in the DSM-IV-TR that has not been in full and
                  sustained remission for at three months from the day of screening (Participant
                  must also have negative urine drug screen at Screening and Baseline; only
                  exception is for benzodiazepines and opiates provided the participant has a valid
                  prescription).

               -  Current diagnosis or history of alcohol or other substance dependence (excluding
                  nicotine or caffeine) as defined in the DSM-IV-TR that has not been in full and
                  sustained remission for at six months from the day of screening.(Participant must
                  also have negative urine drug screen at Screening and Baseline; only exception is
                  for benzodiazepines and opiates provided the participant has a valid
                  prescription).

               -  Presence or history of a clinically significant neurological disorder (including
                  epilepsy) as determined by the investigator.

               -  Neurodegenerative disorder (Alzheimer disease, Parkinson disease, multiple
                  sclerosis, Huntington disease, etc).

               -  Any Axis II disorder that might compromise the study.

               -  History of Rapid Cycling bipolar disorder: Patients who have more than 8 episodes
                  of mood disorder per year.

          5. The participant experienced the first episode of mood disorder after the age of 65
             years.

          6. The participant is on any other medications other than antidepressants (except
             fluvoxamine), mood stabilizers (lithium, valproate, lamotrigine), or atypical
             antipsychotics (risperidone, lithium and/or valproate, the levels should be in the
             specified range: lithium (serum levels up to 1.2 mEq/L); valproate (serum levels up to
             125 mcg/ml) at screening.

          7. The participant has received electroconvulsive therapy, vagal nerve stimulation, or
             repetitive transcranial magnetic stimulation within 6 months prior to Screening.

          8. The participant has started receiving formal cognitive or behavioral therapy,
             systematic psychotherapy within 30 days from screening or plans to initiate such
             therapy during the study (supportive therapy, marital therapy and bereavement
             counseling are allowed).

          9. The participant has a significant risk of suicide according to the investigator's
             clinical judgment or has a score ≥5 on item 10 (suicidal thoughts) of the MADRS or has
             made a suicide attempt in the previous 6 months.

         10. The participant is required to take excluded medications or it is anticipated that the
             participant will require treatment with at least 1 of the disallowed concomitant
             medications during the study.

         11. The participant has a clinically significant unstable illness, for example hepatic
             impairment or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal,
             endocrine, neurological, rheumatologic, immunologic, hematological, infectious,
             dermatological disorder or metabolic disturbance.

         12. The participant has a history or current diagnosis of Fibromyalgia, Chronic Fatigue
             Syndrome, Chronic Pain Syndrome and Sleep apnea.

         13. The participant has a previous history of cancer that had been in remission for less
             than 5 years prior to the first dose of study medication. This criterion does not
             include those participants with basal cell or stage I squamous cell carcinoma of the
             skin.

         14. The participant has 1 or more laboratory value outside the normal range, based on the
             blood or urine samples taken at the Screening Visit, that are considered by the
             investigator to be clinically significant; or the participant has any of the following
             values at the Screening Visit:

               -  A serum creatinine value &gt;1.5 times the upper limits of normal (xULN).

               -  A serum total bilirubin value &gt;1.5 xULN.

               -  A serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value
                  &gt;2 xULN.

         15. The participant has glycosylated hemoglobin (HbA1C) ≥7% at screening and no prior
             diagnosis of diabetes and/or treatment for diabetes. NOTE: Participants with known
             diabetes are not excluded.

         16. The participant has a thyroid stimulating hormone (TSH) value outside the normal range
             at the Screening Visit that is deemed clinically significant by the investigator.
             NOTE: T4 will be checked if TSH is out of range. If T4 is abnormal the participant
             will be excluded.

         17. The participant has clinically significant abnormal vital signs as determined by the
             investigator.

         18. The participant has an abnormal electrocardiogram as determined by the central reader
             and confirmed as clinically significant by the investigator.

         19. The participant has a disease or takes medication that, in the opinion of the
             investigator, could interfere with the assessments of safety, tolerability, or
             efficacy.

         20. The participant has a positive urine drug screen. NOTE: Positive urine drug screens
             for benzodiazepines and opiates for which the participant has a valid prescription
             will be allowed.

         21. The participant has a disease or takes medication that, in the opinion of the
             investigator, could interfere with the assessments of safety, tolerability, or
             efficacy.

         22. The participant has a positive urine drug screen. NOTE: Positive urine drug screens
             for benzodiazepines and opiates for which the participant has a valid prescription
             will be allowed.

         23. The participant, in the opinion of the investigator, is unlikely to comply with the
             clinical study protocol or is unsuitable for any reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Muscle Shoals</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellflower</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Harbor City</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lomita</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Murrieta</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>National City</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rancho Cucamonga</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Redondo Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Ramon</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wildomar</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coral Springs</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leesburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Cloud</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dunwoody</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>East Point</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Smyrna</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suwanee</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gurnee</city>
        <state>Illinois</state>
        <zip>60610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Libertyville</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brownsburg</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manhattan</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elizabethtown</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mandeville</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bloomfield Hills</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hazelwood</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Charles</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cedarhurst</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fresh Meadows</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbiana</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Franklin</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Harleysville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>McMurray</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Media</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lincoln</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indian Land</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clarksville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nassau Bay</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bountiful</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richland</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clarksburg</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Fe</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Antofagasta</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arauco</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elqui</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bello</city>
        <state>Antioquia</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Antioquia</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexicali</city>
        <state>Baja California</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico</city>
        <state>DF</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leon</city>
        <state>Guanajuato</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Merida</city>
        <state>Yucatan</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Peru</country>
  </removed_countries>
  <link>
    <url>http://general.takedapharm.com/content/file/pi.pdf?applicationcode=ab2d7112-8eb3-465a-8fda-35018a9eafb0&amp;fileTypeCode=ROZEREMPI</url>
    <description>Rozerem Package Insert</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2011</study_first_submitted>
  <study_first_submitted_qc>November 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2011</study_first_posted>
  <results_first_submitted>April 8, 2016</results_first_submitted>
  <results_first_submitted_qc>April 8, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 16, 2016</results_first_posted>
  <last_update_submitted>April 8, 2016</last_update_submitted>
  <last_update_submitted_qc>April 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 100 investigative sites in Argentina, Chile, Colombia, Mexico and the United States from 21 December 2011 (first participants signed the informed consent form) to 26 March 2015.</recruitment_details>
      <pre_assignment_details>Participants with a diagnosis of bipolar disorder were enrolled equally in 1 of 4 treatment groups, once a day placebo, Tak-375 SL (ramelteon) 0.1 mg, 0.4 mg or 0.8 mg.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Ramelteon SL placebo-matching, tablets, sublingual (SL) [dissolved under the tongue], once daily, every night at bedtime for up to 9 months.</description>
        </group>
        <group group_id="P2">
          <title>Ramelteon SL 0.1 mg</title>
          <description>Ramelteon SL 0.1 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
        </group>
        <group group_id="P3">
          <title>Ramelteon SL 0.4 mg</title>
          <description>Ramelteon SL 0.4 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
        </group>
        <group group_id="P4">
          <title>Ramelteon SL 0.8 mg</title>
          <description>Ramelteon SL 0.8 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="164"/>
                <participants group_id="P2" count="164"/>
                <participants group_id="P3" count="160"/>
                <participants group_id="P4" count="154"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Analysis Set: Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="163"/>
                <participants group_id="P2" count="164"/>
                <participants group_id="P3" count="159"/>
                <participants group_id="P4" count="154"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="58"/>
                <participants group_id="P4" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="104"/>
                <participants group_id="P3" count="102"/>
                <participants group_id="P4" count="109"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Pretreatment Event or Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Major Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Voluntary Withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Termination</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relapse</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="35"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not Specified</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Ramelteon SL placebo-matching, tablets, sublingual (SL) [dissolved under the tongue], once daily, every night at bedtime for up to 9 months.</description>
        </group>
        <group group_id="B2">
          <title>Ramelteon SL 0.1 mg</title>
          <description>Ramelteon SL 0.1 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
        </group>
        <group group_id="B3">
          <title>Ramelteon SL 0.4 mg</title>
          <description>Ramelteon SL 0.4 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
        </group>
        <group group_id="B4">
          <title>Ramelteon SL 0.8 mg</title>
          <description>Ramelteon SL 0.8 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="164"/>
            <count group_id="B2" value="164"/>
            <count group_id="B3" value="160"/>
            <count group_id="B4" value="154"/>
            <count group_id="B5" value="642"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.21" spread="12.224"/>
                    <measurement group_id="B2" value="42.97" spread="13.262"/>
                    <measurement group_id="B3" value="42.93" spread="11.666"/>
                    <measurement group_id="B4" value="41.71" spread="12.534"/>
                    <measurement group_id="B5" value="42.98" spread="12.440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=50 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="113"/>
                    <measurement group_id="B4" value="112"/>
                    <measurement group_id="B5" value="439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;50 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="92"/>
                    <measurement group_id="B4" value="90"/>
                    <measurement group_id="B5" value="367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="64"/>
                    <measurement group_id="B5" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="46"/>
                    <measurement group_id="B5" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hispanic and Non-Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="106"/>
                    <measurement group_id="B4" value="108"/>
                    <measurement group_id="B5" value="427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="117"/>
                    <measurement group_id="B4" value="104"/>
                    <measurement group_id="B5" value="455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="115"/>
                    <measurement group_id="B4" value="114"/>
                    <measurement group_id="B5" value="467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168.65" spread="10.159"/>
                    <measurement group_id="B2" value="168.56" spread="9.790"/>
                    <measurement group_id="B3" value="167.49" spread="10.235"/>
                    <measurement group_id="B4" value="168.47" spread="9.608"/>
                    <measurement group_id="B5" value="168.30" spread="9.943"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87.04" spread="21.148"/>
                    <measurement group_id="B2" value="87.52" spread="21.265"/>
                    <measurement group_id="B3" value="88.68" spread="22.291"/>
                    <measurement group_id="B4" value="85.71" spread="21.386"/>
                    <measurement group_id="B5" value="87.25" spread="21.500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>BMI is calculated using the weight collected at the first screening visit (Visit 1): BMI=weight(kg)/[height(m)]^2</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.68" spread="7.351"/>
                    <measurement group_id="B2" value="30.66" spread="6.382"/>
                    <measurement group_id="B3" value="31.52" spread="7.108"/>
                    <measurement group_id="B4" value="30.11" spread="6.702"/>
                    <measurement group_id="B5" value="30.75" spread="6.900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Classification</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Participant Has Never Smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="62"/>
                    <measurement group_id="B5" value="281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant is a Current Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="63"/>
                    <measurement group_id="B5" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant is an Ex-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participant Drinking Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Has Never Drunk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="58"/>
                    <measurement group_id="B5" value="261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-Drinker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current Drinker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>If Drinker, Amount Consumed</title>
          <description>Only participants with drinking status Current Drinker are accounted for: N=49, 43, 47, 55 in each treatment arm, respectively.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;4 Drinks per Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 4 Drinks per Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Does Participant Consume Caffeine?</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="122"/>
                    <measurement group_id="B4" value="127"/>
                    <measurement group_id="B5" value="492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time From Randomization to Any Relapse</title>
        <description>The time from randomization to relapse over 12 months double-blind treatment period as determined by the Principal Investigator (PI) or defined by any of the following criteria: depression [Montgomery-Åsberg Depression Rating Scale (MADRS) score ≥16]; mania/hypomania [Young Mania Rating Scale (YMRS) total score ≥14]; mixed episode [MADRS score ≥16 and YMRS total score ≥16]; or, whether participant receives psychiatric hospitalization for bipolar disorder, electroconvulsive therapy (ECT) or any psychotropic medication change prescribed for the treatment of depression, mania/hypomania or mixed episodes.</description>
        <time_frame>Randomization to Month 12 double-blind treatment period</time_frame>
        <population>Full Analysis Set included all randomized participants who received at least 1 dose of study drug and had at least one valid post-baseline value for assessment of primary efficacy. Participants without relapse were censored.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Ramelteon SL placebo-matching, tablets, sublingual (SL) [dissolved under the tongue], once daily, every night at bedtime for up to 9 months.</description>
          </group>
          <group group_id="O2">
            <title>Ramelteon SL 0.1 mg</title>
            <description>Ramelteon SL 0.1 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
          </group>
          <group group_id="O3">
            <title>Ramelteon SL 0.4 mg</title>
            <description>Ramelteon SL 0.4 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
          </group>
          <group group_id="O4">
            <title>Ramelteon SL 0.8 mg</title>
            <description>Ramelteon SL 0.8 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Randomization to Any Relapse</title>
          <description>The time from randomization to relapse over 12 months double-blind treatment period as determined by the Principal Investigator (PI) or defined by any of the following criteria: depression [Montgomery-Åsberg Depression Rating Scale (MADRS) score ≥16]; mania/hypomania [Young Mania Rating Scale (YMRS) total score ≥14]; mixed episode [MADRS score ≥16 and YMRS total score ≥16]; or, whether participant receives psychiatric hospitalization for bipolar disorder, electroconvulsive therapy (ECT) or any psychotropic medication change prescribed for the treatment of depression, mania/hypomania or mixed episodes.</description>
          <population>Full Analysis Set included all randomized participants who received at least 1 dose of study drug and had at least one valid post-baseline value for assessment of primary efficacy. Participants without relapse were censored.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="154"/>
                <count group_id="O4" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="248.3" spread="8.11"/>
                    <measurement group_id="O2" value="287.7" spread="8.83"/>
                    <measurement group_id="O3" value="253.1" spread="7.52"/>
                    <measurement group_id="O4" value="223.9" spread="7.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.286</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.77</param_value>
            <ci_percent>98.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>1.39</ci_upper_limit>
            <estimate_desc>Cox proportional hazards model with only treatment in the model.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.332</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.78</param_value>
            <ci_percent>98.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.43</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
            <estimate_desc>Cox proportional hazards model with only treatment in the model.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.808</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.06</param_value>
            <ci_percent>98.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>1.86</ci_upper_limit>
            <estimate_desc>Cox proportional hazards model with only treatment in the model.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.286</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>98.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>1.61</ci_upper_limit>
            <estimate_desc>Cox proportional hazards model with treatment, pooled center, age, gender, and baseline MADRS score in the model.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.332</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.79</param_value>
            <ci_percent>98.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>1.49</ci_upper_limit>
            <estimate_desc>Cox proportional hazards model with treatment, pooled center, age, gender, and baseline MADRS score in the model.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.808</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.08</param_value>
            <ci_percent>98.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>1.95</ci_upper_limit>
            <estimate_desc>Cox proportional hazards model with treatment, pooled center, age, gender, and baseline MADRS score in the model.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Randomization to Relapse Due to Depression</title>
        <description>Relapse due to depression determined by any of the following criteria during the 12-month double-blind treatment period: PI judgment, MADRS ≥16, psychiatry hospitalization, ECT or any psychotropic medication change prescribed for the treatment of depressive episodes.</description>
        <time_frame>Randomization to Month 12 double-blind treatment period</time_frame>
        <population>Full Analysis Set included all randomized participants who received at least 1 dose of study drug and had at least one valid post-baseline value for assessment of primary efficacy. Participants without relapse were censored.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Ramelteon SL placebo-matching, tablets, sublingual (SL) [dissolved under the tongue], once daily, every night at bedtime for up to 9 months.</description>
          </group>
          <group group_id="O2">
            <title>Ramelteon SL 0.1 mg</title>
            <description>Ramelteon SL 0.1 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
          </group>
          <group group_id="O3">
            <title>Ramelteon SL 0.4 mg</title>
            <description>Ramelteon SL 0.4 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
          </group>
          <group group_id="O4">
            <title>Ramelteon SL 0.8 mg</title>
            <description>Ramelteon SL 0.8 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Randomization to Relapse Due to Depression</title>
          <description>Relapse due to depression determined by any of the following criteria during the 12-month double-blind treatment period: PI judgment, MADRS ≥16, psychiatry hospitalization, ECT or any psychotropic medication change prescribed for the treatment of depressive episodes.</description>
          <population>Full Analysis Set included all randomized participants who received at least 1 dose of study drug and had at least one valid post-baseline value for assessment of primary efficacy. Participants without relapse were censored.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="154"/>
                <count group_id="O4" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="256.5" spread="7.70"/>
                    <measurement group_id="O2" value="242.1" spread="5.56"/>
                    <measurement group_id="O3" value="260.8" spread="7.03"/>
                    <measurement group_id="O4" value="224.2" spread="6.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Randomization to Relapse Due to Mania/Hypomania or Mixed Episode</title>
        <description>Relapse due to mania/hypomania or mixed episode is determined by any of the following criteria: PI judgment, mania/hypomania [YMRS ≥16], mixed episode [MADRS ≥16 and YMRS ≥16], psychiatry hospitalization, ECT or any psychotropic medication change prescribed for the treatment of mania/hypomania or mixed episodes.</description>
        <time_frame>Randomization to Month 12 double-blind treatment period</time_frame>
        <population>Full Analysis Set included all randomized participants who received at least 1 dose of study drug and had at least one valid post-baseline value for assessment of primary efficacy. Participants without relapse were censored.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Ramelteon SL placebo-matching, tablets, sublingual (SL) [dissolved under the tongue], once daily, every night at bedtime for up to 9 months.</description>
          </group>
          <group group_id="O2">
            <title>Ramelteon SL 0.1 mg</title>
            <description>Ramelteon SL 0.1 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
          </group>
          <group group_id="O3">
            <title>Ramelteon SL 0.4 mg</title>
            <description>Ramelteon SL 0.4 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
          </group>
          <group group_id="O4">
            <title>Ramelteon SL 0.8 mg</title>
            <description>Ramelteon SL 0.8 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Randomization to Relapse Due to Mania/Hypomania or Mixed Episode</title>
          <description>Relapse due to mania/hypomania or mixed episode is determined by any of the following criteria: PI judgment, mania/hypomania [YMRS ≥16], mixed episode [MADRS ≥16 and YMRS ≥16], psychiatry hospitalization, ECT or any psychotropic medication change prescribed for the treatment of mania/hypomania or mixed episodes.</description>
          <population>Full Analysis Set included all randomized participants who received at least 1 dose of study drug and had at least one valid post-baseline value for assessment of primary efficacy. Participants without relapse were censored.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="154"/>
                <count group_id="O4" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150.2" spread="1.60"/>
                    <measurement group_id="O2" value="319.3" spread="6.07"/>
                    <measurement group_id="O3" value="269.5" spread="3.69"/>
                    <measurement group_id="O4" value="255.5" spread="5.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Randomization to Relapse Due to Depression From PI Judgement and/or MADRS ≥16</title>
        <description>The time from randomization to relapse event during the 12 month double-blind treatment period due to depression, determined by the PI judgement and/or a MADRS score ≥16. MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (i.e., apparent sadness, reported sadness, inner tension, etc.) rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score range from 0 to 60. Higher scores indicate greater severity of symptoms.</description>
        <time_frame>Randomization to Month 12 double-blind treatment period</time_frame>
        <population>Full Analysis Set included all randomized participants who received at least 1 dose of study drug and had at least one valid post-baseline value for assessment of primary efficacy. Participants without relapse were censored.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Ramelteon SL placebo-matching, tablets, sublingual (SL) [dissolved under the tongue], once daily, every night at bedtime for up to 9 months.</description>
          </group>
          <group group_id="O2">
            <title>Ramelteon SL 0.1 mg</title>
            <description>Ramelteon SL 0.1 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
          </group>
          <group group_id="O3">
            <title>Ramelteon SL 0.4 mg</title>
            <description>Ramelteon SL 0.4 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
          </group>
          <group group_id="O4">
            <title>Ramelteon SL 0.8 mg</title>
            <description>Ramelteon SL 0.8 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Randomization to Relapse Due to Depression From PI Judgement and/or MADRS ≥16</title>
          <description>The time from randomization to relapse event during the 12 month double-blind treatment period due to depression, determined by the PI judgement and/or a MADRS score ≥16. MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (i.e., apparent sadness, reported sadness, inner tension, etc.) rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score range from 0 to 60. Higher scores indicate greater severity of symptoms.</description>
          <population>Full Analysis Set included all randomized participants who received at least 1 dose of study drug and had at least one valid post-baseline value for assessment of primary efficacy. Participants without relapse were censored.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="154"/>
                <count group_id="O4" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="265.0" spread="7.14"/>
                    <measurement group_id="O2" value="245.1" spread="5.22"/>
                    <measurement group_id="O3" value="262.5" spread="6.90"/>
                    <measurement group_id="O4" value="224.2" spread="6.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Randomization to Relapse Due to Mania/Hypomania</title>
        <description>Relapse due to mania/hypomania is determined by the primary investigator (PI) judgement and/or a YMRS total score ≥16. YMRS is a 11 item scale with four items scale to assess manic symptoms, rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe), with 7 items rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe) with higher scores reflecting greater levels of mania. The YMRS total score is calculated as the sum of the 11 individual item scores and ranges from 0-60.</description>
        <time_frame>Randomization to 12 Month double-blind treatment period</time_frame>
        <population>Full Analysis Set included all randomized participants who received at least 1 dose of study drug and had at least one valid post-baseline value for assessment of primary efficacy. Participants without relapse were censored.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Ramelteon SL placebo-matching, tablets, sublingual (SL) [dissolved under the tongue], once daily, every night at bedtime for up to 9 months.</description>
          </group>
          <group group_id="O2">
            <title>Ramelteon SL 0.1 mg</title>
            <description>Ramelteon SL 0.1 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
          </group>
          <group group_id="O3">
            <title>Ramelteon SL 0.4 mg</title>
            <description>Ramelteon SL 0.4 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
          </group>
          <group group_id="O4">
            <title>Ramelteon SL 0.8 mg</title>
            <description>Ramelteon SL 0.8 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Randomization to Relapse Due to Mania/Hypomania</title>
          <description>Relapse due to mania/hypomania is determined by the primary investigator (PI) judgement and/or a YMRS total score ≥16. YMRS is a 11 item scale with four items scale to assess manic symptoms, rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe), with 7 items rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe) with higher scores reflecting greater levels of mania. The YMRS total score is calculated as the sum of the 11 individual item scores and ranges from 0-60.</description>
          <population>Full Analysis Set included all randomized participants who received at least 1 dose of study drug and had at least one valid post-baseline value for assessment of primary efficacy. Participants without relapse were censored.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="154"/>
                <count group_id="O4" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150.7" spread="1.60"/>
                    <measurement group_id="O2" value="328.8" spread="4.53"/>
                    <measurement group_id="O3" value="274.8" spread="2.20"/>
                    <measurement group_id="O4" value="263.3" spread="3.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Randomization to Relapse Due to Mixed Episode</title>
        <description>Relapse due to Mixed episode is determined by PI judgement and/or MADRS score ≥16 and YMRS total score ≥16. MADRS is a 10-item scale that measures overall severity of depressive symptoms rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score range from 0 to 60. YMRS is a four item scale to assess manic symptoms, rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe), with 7 items rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score is calculated as the sum of the 11 individual item scores and ranges from 0-60.</description>
        <time_frame>Randomization to Month 12 double-blind treatment period</time_frame>
        <population>Full Analysis Set included all randomized participants who received at least 1 dose of study drug and had at least one valid post-baseline value for assessment of primary efficacy. Participants without relapse were censored.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Ramelteon SL placebo-matching, tablets, sublingual (SL) [dissolved under the tongue], once daily, every night at bedtime for up to 9 months.</description>
          </group>
          <group group_id="O2">
            <title>Ramelteon SL 0.1 mg</title>
            <description>Ramelteon SL 0.1 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
          </group>
          <group group_id="O3">
            <title>Ramelteon SL 0.4 mg</title>
            <description>Ramelteon SL 0.4 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
          </group>
          <group group_id="O4">
            <title>Ramelteon SL 0.8 mg</title>
            <description>Ramelteon SL 0.8 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Randomization to Relapse Due to Mixed Episode</title>
          <description>Relapse due to Mixed episode is determined by PI judgement and/or MADRS score ≥16 and YMRS total score ≥16. MADRS is a 10-item scale that measures overall severity of depressive symptoms rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score range from 0 to 60. YMRS is a four item scale to assess manic symptoms, rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe), with 7 items rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score is calculated as the sum of the 11 individual item scores and ranges from 0-60.</description>
          <population>Full Analysis Set included all randomized participants who received at least 1 dose of study drug and had at least one valid post-baseline value for assessment of primary efficacy. Participants without relapse were censored.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="154"/>
                <count group_id="O4" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147.6" spread="0.63"/>
                    <measurement group_id="O2" value="150.2" spread="1.53"/>
                    <measurement group_id="O3" value="96.0" spread="0.89"/>
                    <measurement group_id="O4" value="180.5" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Randomization to Relapse Due to Psychiatric Hospitalization for Bipolar Disorder</title>
        <description>The time from randomization to relapse event during the 12 months double-blind treatment period due to psychiatric hospitalization for bipolar disorder.</description>
        <time_frame>Randomization to Month 12 double-blind treatment period</time_frame>
        <population>Full Analysis Set included all randomized participants who received at least 1 dose of study drug and had at least one valid post-baseline value for assessment of primary efficacy. Participants without relapse were censored.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Ramelteon SL placebo-matching, tablets, sublingual (SL) [dissolved under the tongue], once daily, every night at bedtime for up to 9 months.</description>
          </group>
          <group group_id="O2">
            <title>Ramelteon SL 0.1 mg</title>
            <description>Ramelteon SL 0.1 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
          </group>
          <group group_id="O3">
            <title>Ramelteon SL 0.4 mg</title>
            <description>Ramelteon SL 0.4 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
          </group>
          <group group_id="O4">
            <title>Ramelteon SL 0.8 mg</title>
            <description>Ramelteon SL 0.8 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Randomization to Relapse Due to Psychiatric Hospitalization for Bipolar Disorder</title>
          <description>The time from randomization to relapse event during the 12 months double-blind treatment period due to psychiatric hospitalization for bipolar disorder.</description>
          <population>Full Analysis Set included all randomized participants who received at least 1 dose of study drug and had at least one valid post-baseline value for assessment of primary efficacy. Participants without relapse were censored.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="154"/>
                <count group_id="O4" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198.6" spread="2.29"/>
                    <measurement group_id="O2" value="34.8" spread="0.20"/>
                    <measurement group_id="O3" value="70.6" spread="0.52"/>
                    <measurement group_id="O4" value="251.3" spread="2.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Randomization to Relapse Due to Electroconvulsive Therapy (ECT) Administration</title>
        <description>The time from randomization to relapse event during the 12 month double-blind treatment period due to ECT.</description>
        <time_frame>Randomization to Month 12 double-blind treatment period</time_frame>
        <population>Full Analysis Set included all randomized participants who received at least 1 dose of study drug and had at least one valid post-baseline value for assessment of primary efficacy. Participants without relapse were censored.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Ramelteon SL placebo-matching, tablets, sublingual (SL) [dissolved under the tongue], once daily, every night at bedtime for up to 9 months.</description>
          </group>
          <group group_id="O2">
            <title>Ramelteon SL 0.1 mg</title>
            <description>Ramelteon SL 0.1 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
          </group>
          <group group_id="O3">
            <title>Ramelteon SL 0.4 mg</title>
            <description>Ramelteon SL 0.4 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
          </group>
          <group group_id="O4">
            <title>Ramelteon SL 0.8 mg</title>
            <description>Ramelteon SL 0.8 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Randomization to Relapse Due to Electroconvulsive Therapy (ECT) Administration</title>
          <description>The time from randomization to relapse event during the 12 month double-blind treatment period due to ECT.</description>
          <population>Full Analysis Set included all randomized participants who received at least 1 dose of study drug and had at least one valid post-baseline value for assessment of primary efficacy. Participants without relapse were censored.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="154"/>
                <count group_id="O4" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No relapses due to ECT.</measurement>
                    <measurement group_id="O2" value="NA">No relapses due to ECT.</measurement>
                    <measurement group_id="O3" value="NA">No relapses due to ECT.</measurement>
                    <measurement group_id="O4" value="NA">No relapses due to ECT.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Randomization to Relapse Due to Psychotropic Medication Change Prescribed for the Treatment of Depression, Mania/Hypomania or Mixed Episodes</title>
        <description>The time from randomization to relapse event during the 12 month double-blind treatment period due to any psychotropic medication change prescribed for the treatment of depression, mania/hypomania or mixed episode(s).</description>
        <time_frame>Randomization to Month 12 double-blind treatment period</time_frame>
        <population>Full Analysis Set included all randomized participants who received at least 1 dose of study drug and had at least one valid post-baseline value for assessment of primary efficacy. Participants without relapse were censored.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Ramelteon SL placebo-matching, tablets, sublingual (SL) [dissolved under the tongue], once daily, every night at bedtime for up to 9 months.</description>
          </group>
          <group group_id="O2">
            <title>Ramelteon SL 0.1 mg</title>
            <description>Ramelteon SL 0.1 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
          </group>
          <group group_id="O3">
            <title>Ramelteon SL 0.4 mg</title>
            <description>Ramelteon SL 0.4 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
          </group>
          <group group_id="O4">
            <title>Ramelteon SL 0.8 mg</title>
            <description>Ramelteon SL 0.8 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Randomization to Relapse Due to Psychotropic Medication Change Prescribed for the Treatment of Depression, Mania/Hypomania or Mixed Episodes</title>
          <description>The time from randomization to relapse event during the 12 month double-blind treatment period due to any psychotropic medication change prescribed for the treatment of depression, mania/hypomania or mixed episode(s).</description>
          <population>Full Analysis Set included all randomized participants who received at least 1 dose of study drug and had at least one valid post-baseline value for assessment of primary efficacy. Participants without relapse were censored.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="154"/>
                <count group_id="O4" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197.8" spread="2.33"/>
                    <measurement group_id="O2" value="18.9" spread="0.13"/>
                    <measurement group_id="O3" value="257.9" spread="2.69"/>
                    <measurement group_id="O4" value="55.7" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Randomization to Study Withdrawal for Any Reason</title>
        <description>The time from randomization to study withdrawal during the 12 month double-blind treatment period. Withdrawal includes pretreatment event/adverse event; liver function test abnormalities; major protocol deviation; lost to follow-up; voluntary withdrawal; study termination; pregnancy; lack of efficacy; participant has a depressive, mania/hypomania or mixed episode; is hospitalized for psychiatric reasons; receives electroconvulsive therapy for bipolar disorder; receives any psychotropic medication change prescribed for the treatment of depression, mania/hypomania or mixed episodes; or any other reason.</description>
        <time_frame>Randomization to Month 12 double-blind treatment period</time_frame>
        <population>Full Analysis Set included all randomized participants who received at least 1 dose of study drug and had at least one valid post-baseline value for assessment of primary efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Ramelteon SL placebo-matching, tablets, sublingual (SL) [dissolved under the tongue], once daily, every night at bedtime for up to 9 months.</description>
          </group>
          <group group_id="O2">
            <title>Ramelteon SL 0.1 mg</title>
            <description>Ramelteon SL 0.1 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
          </group>
          <group group_id="O3">
            <title>Ramelteon SL 0.4 mg</title>
            <description>Ramelteon SL 0.4 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
          </group>
          <group group_id="O4">
            <title>Ramelteon SL 0.8 mg</title>
            <description>Ramelteon SL 0.8 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Randomization to Study Withdrawal for Any Reason</title>
          <description>The time from randomization to study withdrawal during the 12 month double-blind treatment period. Withdrawal includes pretreatment event/adverse event; liver function test abnormalities; major protocol deviation; lost to follow-up; voluntary withdrawal; study termination; pregnancy; lack of efficacy; participant has a depressive, mania/hypomania or mixed episode; is hospitalized for psychiatric reasons; receives electroconvulsive therapy for bipolar disorder; receives any psychotropic medication change prescribed for the treatment of depression, mania/hypomania or mixed episodes; or any other reason.</description>
          <population>Full Analysis Set included all randomized participants who received at least 1 dose of study drug and had at least one valid post-baseline value for assessment of primary efficacy.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="154"/>
                <count group_id="O4" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240.6" spread="11.44"/>
                    <measurement group_id="O2" value="226.8" spread="10.48"/>
                    <measurement group_id="O3" value="226.9" spread="10.88"/>
                    <measurement group_id="O4" value="208.7" spread="11.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life, Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF) Total Score</title>
        <description>Q-LES-Q-SF is a self-administered 16-item questionnaire to assess the degree of enjoyment and satisfaction experienced by patients in various areas of daily functioning. It includes 30 items across five subscales (daily activities, clothing, diet/food habits, relationship, psychological well-being and distress), scored on a 6-point Likert scale with subscale and total score ranging from 0 (none) to 5 (all the time). For reporting purposes, the scores are reversed and higher scores reflect improved quality of life and positive changes relative to baseline indicate improved quality of life.</description>
        <time_frame>Baseline and Months 1, 2, 3, 4, 5, 6, 7, 8, 10 and 12</time_frame>
        <population>Participants from the Full Analysis Set, all randomized participants who received at least 1 dose of study drug and had at least one valid post-baseline value for assessment of primary efficacy, with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Ramelteon SL placebo-matching, tablets, sublingual (SL) [dissolved under the tongue], once daily, every night at bedtime for up to 9 months.</description>
          </group>
          <group group_id="O2">
            <title>Ramelteon SL 0.1 mg</title>
            <description>Ramelteon SL 0.1 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
          </group>
          <group group_id="O3">
            <title>Ramelteon SL 0.4 mg</title>
            <description>Ramelteon SL 0.4 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
          </group>
          <group group_id="O4">
            <title>Ramelteon SL 0.8 mg</title>
            <description>Ramelteon SL 0.8 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life, Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF) Total Score</title>
          <description>Q-LES-Q-SF is a self-administered 16-item questionnaire to assess the degree of enjoyment and satisfaction experienced by patients in various areas of daily functioning. It includes 30 items across five subscales (daily activities, clothing, diet/food habits, relationship, psychological well-being and distress), scored on a 6-point Likert scale with subscale and total score ranging from 0 (none) to 5 (all the time). For reporting purposes, the scores are reversed and higher scores reflect improved quality of life and positive changes relative to baseline indicate improved quality of life.</description>
          <population>Participants from the Full Analysis Set, all randomized participants who received at least 1 dose of study drug and had at least one valid post-baseline value for assessment of primary efficacy, with available data.</population>
          <units>percent of maximum total score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="154"/>
                <count group_id="O4" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=115, 129, 121, 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.7" spread="17.00"/>
                    <measurement group_id="O2" value="65.1" spread="16.57"/>
                    <measurement group_id="O3" value="68.6" spread="15.71"/>
                    <measurement group_id="O4" value="65.8" spread="15.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1 (n=113, 127, 121, 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.3" spread="14.68"/>
                    <measurement group_id="O2" value="68.5" spread="15.48"/>
                    <measurement group_id="O3" value="70.2" spread="14.76"/>
                    <measurement group_id="O4" value="68.1" spread="14.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 (n=115, 128, 121, 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.3" spread="16.24"/>
                    <measurement group_id="O2" value="68.7" spread="15.11"/>
                    <measurement group_id="O3" value="70.6" spread="15.07"/>
                    <measurement group_id="O4" value="67.4" spread="15.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=115, 129, 121, 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.5" spread="15.89"/>
                    <measurement group_id="O2" value="69.0" spread="14.83"/>
                    <measurement group_id="O3" value="70.0" spread="15.68"/>
                    <measurement group_id="O4" value="66.2" spread="16.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4 (n=115, 129, 121, 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.8" spread="17.18"/>
                    <measurement group_id="O2" value="68.9" spread="15.67"/>
                    <measurement group_id="O3" value="69.3" spread="15.11"/>
                    <measurement group_id="O4" value="66.9" spread="17.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 (n=115, 129, 121, 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.2" spread="16.43"/>
                    <measurement group_id="O2" value="69.6" spread="16.86"/>
                    <measurement group_id="O3" value="69.6" spread="15.22"/>
                    <measurement group_id="O4" value="66.0" spread="16.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=115, 129, 121, 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.1" spread="17.37"/>
                    <measurement group_id="O2" value="68.4" spread="17.41"/>
                    <measurement group_id="O3" value="68.1" spread="16.09"/>
                    <measurement group_id="O4" value="67.2" spread="16.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7 (n=115, 129, 121, 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.0" spread="16.80"/>
                    <measurement group_id="O2" value="70.4" spread="15.98"/>
                    <measurement group_id="O3" value="69.7" spread="15.80"/>
                    <measurement group_id="O4" value="65.8" spread="17.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8 (n=115, 129, 121, 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.7" spread="16.63"/>
                    <measurement group_id="O2" value="71.0" spread="15.17"/>
                    <measurement group_id="O3" value="69.0" spread="17.24"/>
                    <measurement group_id="O4" value="66.8" spread="17.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 (n=115, 129, 121, 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.9" spread="16.91"/>
                    <measurement group_id="O2" value="71.1" spread="16.57"/>
                    <measurement group_id="O3" value="70.2" spread="15.41"/>
                    <measurement group_id="O4" value="66.5" spread="17.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=115, 129, 121, 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.5" spread="17.69"/>
                    <measurement group_id="O2" value="70.9" spread="16.54"/>
                    <measurement group_id="O3" value="70.0" spread="15.97"/>
                    <measurement group_id="O4" value="66.8" spread="17.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Approximately 30 days after the last dose of study drug (up to 12 Weeks)</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Ramelteon SL placebo-matching, tablets, sublingual (SL) [dissolved under the tongue], once daily, every night at bedtime for up to 9 months.</description>
        </group>
        <group group_id="E2">
          <title>Ramelteon SL 0.1 mg</title>
          <description>Ramelteon SL 0.1 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
        </group>
        <group group_id="E3">
          <title>Ramelteon SL 0.4 mg</title>
          <description>Ramelteon SL 0.4 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
        </group>
        <group group_id="E4">
          <title>Ramelteon SL 0.8 mg</title>
          <description>Ramelteon SL 0.8 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version:17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pharyngeal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Bipolar I disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Victim of crime</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version:17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director, Clinical Science</name_or_title>
      <organization>Takeda</organization>
      <phone>1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

